The Science Hat - Season 2 Episode 5 - Hot Copper - More precious than gold

Copper-64 and copper-67 are ideally suited for diagnosis and treatment of cancer and offer a number of advantages, including logistical, manufacturing and environmental benefits. This differentiates Targeted Copper Theranostics from a myriad of other radiopharmaceuticals and enables Clarity to employ the big pharma model of centralised manufacturing of both diagnostic and therapeutic products under cGMP under one roof.
Watch season 2 episode 5 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the "perfect pairing" of copper isotopes and how it is positioned to launch radiopharmaceuticals into the large oncology market, overcoming numerous challenges of the current-generation of diagnostics and therapies.
Click on the following link to watch previous episodes of the Science Hat podcast and learn more about Clarity’s TCT platforms: www.claritypha...